Filtered By:
Management: WHO
Procedure: Liver Transplant
Countries: USA Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
A Novel Deep Neural Network Model for Multi-Label Chronic Disease Prediction
Conclusions concludes this work along with future work.
Dataset and Data Preprocessing
In the work, we mainly focus on multiple chronic disease classification. It can be formulated into a multi-label classification problem. There are three common chronic diseases are selected from the physical examination records: hypertension (H), diabetes (D), and fatty liver (FL).
In the experiments, the physical examination datasets are collected from a local medical center, which contain 110,300 physical examination records from about 80,000 anonymous patients (Li et al., 2017a,b). Sixty-two feature items are selected from over 100...
Source: Frontiers in Genetics - April 23, 2019 Category: Genetics & Stem Cells Source Type: research
